Related Experiment Video

Updated: Mar 25, 2026

Acute Kidney Injury Model Induced by Cisplatin in Adult Zebrafish
13:25

Acute Kidney Injury Model Induced by Cisplatin in Adult Zebrafish

Published on: May 15, 2021

6.8K

Risk Factors for Febrile Neutropenia in Children With Solid Tumors Treated With Cisplatin-based Chemotherapy

Osvaldo D Castelán-Martínez1, Felipe Rodríguez-Islas, Jessica L Vargas-Neri

  • 1*Facultad de Estudios Superiores Zaragoza ¶Faculty of Medicine, Universidad Nacional Autónoma de México †Clinical Epidemiology Unit, Hospital Infantil de México Federico Gómez ‡Pharmacology Department, Centro de Investigación y Estudios Avanzados del Instituto Politécnico Nacional §Onco-Hematology Department, Hospital Infantil de México Federico Gómez ∥Oncology Department, Hospital de Pediatría "Dr. Silvestre Frenk Freud" #Coordination of Health Research, Instituto Mexicano del Seguro Social, Mexico City, Mexico.

Journal of Pediatric Hematology/Oncology
|February 25, 2016
PubMed

Insights

Febrile neutropenia (FN) is a significant risk in pediatric cancer patients receiving cisplatin-based chemotherapy. Anthracyclines, hypomagnesaemia, and radiotherapy were identified as key independent risk factors for developing FN.

Area of Science:

  • Pediatric Oncology
  • Clinical Pharmacology
  • Hematology

Background:

  • Febrile neutropenia (FN) is a serious adverse drug reaction associated with cisplatin-based chemotherapy (CDDPBC).
  • Pediatric patients with solid tumors undergoing CDDPBC are particularly vulnerable to FN.
  • Understanding FN incidence and risk factors is crucial for improving patient outcomes.

Purpose of the Study:

  • To determine the incidence of FN in pediatric patients with solid tumors treated with CDDPBC.
  • To identify independent risk factors associated with FN in this patient population.

Main Methods:

  • A cohort study involving 139 pediatric patients treated with CDDPBC.
  • Patients were monitored from the first chemotherapy cycle for up to 6 months post-treatment.
  • Statistical analyses, including relative risks and multiple logistic regression, were used to identify risk factors.

Main Results:

  • The overall incidence of FN was 62.5%.
  • Independent risk factors for FN included chemotherapy regimens containing anthracyclines (OR=19.44), hypomagnesaemia (OR=8.20), and radiotherapy (OR=6.67).

Conclusions:

  • Anthracycline-containing chemotherapy regimens, hypomagnesaemia, and radiotherapy are significant independent risk factors for FN in pediatric patients receiving CDDPBC.
  • These findings highlight the need for vigilant monitoring and potential interventions in pediatric oncology patients with solid tumors undergoing CDDPBC.

More Related Videos

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

3.3K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

11.1K

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
735
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
786
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
369
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
148
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
458
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
66